An update on emerging immunological targets and their inhibitors in the treatment of psoriasis
Authors:
- 28 October 2022
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 113 (Pt A) , 109341
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory DiseasesDermatology and Therapy, 2013
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunityNature Genetics, 2012
- The Safety of Systemic Treatments That Can Be Used for Geriatric Psoriasis Patients: A ReviewDermatology Research and Practice, 2012
- Evolution and classification of the CRISPR–Cas systemsNature Reviews Microbiology, 2011
- Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasisBritish Journal of Pharmacology, 2010
- Translational Mini-Review Series on Th17 Cells: Development of mouse and human T helper 17 cellsClinical and Experimental Immunology, 2009
- AP-1 Activated by Toll-like Receptors Regulates Expression of IL-23 p19Journal of Biological Chemistry, 2009
- Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- A Large-Scale Genetic Association Study Confirms IL12B and Leads to the Identification of IL23R as Psoriasis-Risk GenesThe American Journal of Human Genetics, 2007
- The IL-23/IL-17 axis in inflammationJournal of Clinical Investigation, 2006